Alum adjuvant is more effective than MF59 at prompting early germinal center formation in response to peptide-protein conjugates and enhancing efficacy of a vaccine against opioid use disorders.


Journal

Human vaccines & immunotherapeutics
ISSN: 2164-554X
Titre abrégé: Hum Vaccin Immunother
Pays: United States
ID NLM: 101572652

Informations de publication

Date de publication:
2019
Historique:
pubmed: 10 1 2019
medline: 29 2 2020
entrez: 10 1 2019
Statut: ppublish

Résumé

Opioid use disorders (OUD) and fatal overdoses are a national emergency in the United States. Therapeutic vaccines offer a promising strategy to treat OUD and reduce the incidence of overdose. Immunization with opioid-based haptens conjugated to immunogenic carriers elicits opioid-specific antibodies that block opioid distribution to the brain and reduce opioid-induced behavior and toxicity in pre-clinical models. This study tested whether the efficacy of a lead oxycodone conjugate vaccine was improved by formulation in either aluminum hydroxide or the squalene-based oil-in-water emulsion MF59 adjuvant, which was recently FDA-approved for influenza vaccines in subjects 65

Identifiants

pubmed: 30625019
doi: 10.1080/21645515.2018.1558697
pmc: PMC6605845
doi:

Substances chimiques

Adjuvants, Immunologic 0
Alum Compounds 0
MF59 oil emulsion 0
Peptides 0
Polysorbates 0
Proteins 0
Vaccines, Conjugate 0
aluminum sulfate 34S289N54E
Squalene 7QWM220FJH
Oxycodone CD35PMG570

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

909-917

Subventions

Organisme : NIDA NIH HHS
ID : R01 DA041730
Pays : United States
Organisme : NIDA NIH HHS
ID : T32 DA007097
Pays : United States
Organisme : NIDA NIH HHS
ID : U01 DA038876
Pays : United States

Références

Proc Natl Acad Sci U S A. 2008 Jul 29;105(30):10501-6
pubmed: 18650390
J Immunol. 2015 Aug 15;195(4):1617-27
pubmed: 26170383
J Med Chem. 2013 Feb 14;56(3):915-23
pubmed: 23249238
Nat Protoc. 2009;4(4):565-81
pubmed: 19373228
Pediatr Infect Dis J. 2012 Jul;31(7):e92-8
pubmed: 22481427
Med Care. 2016 Oct;54(10):901-6
pubmed: 27623005
J Immunol. 2008 Apr 15;180(8):5402-12
pubmed: 18390722
Mol Pharm. 2018 Nov 5;15(11):4947-4962
pubmed: 30240216
NPJ Vaccines. 2017 May 2;2:13
pubmed: 29263870
J Clin Pharmacol. 2014 Apr;54(4):468-77
pubmed: 24243216
ACS Chem Neurosci. 2018 Jun 20;9(6):1269-1275
pubmed: 29558798
J Immunol Methods. 2014 Mar;405:74-86
pubmed: 24462800
Nat Rev Microbiol. 2007 Jul;5(7):505-17
pubmed: 17558426
PLoS One. 2017 Dec 1;12(12):e0184876
pubmed: 29194445
Am J Drug Alcohol Abuse. 2016 Sep;42(5):539-549
pubmed: 27211522
Hum Vaccin Immunother. 2014;10(6):1701-10
pubmed: 24732325
Immunity. 2007 Nov;27(5):687-90
pubmed: 18031690
Sci Rep. 2018 Apr 3;8(1):5508
pubmed: 29615715
J Am Chem Soc. 2017 Jun 28;139(25):8601-8611
pubmed: 28574716
J Pharmacol Exp Ther. 2013 Feb;344(2):397-406
pubmed: 23220743
J Gen Virol. 2006 Aug;87(Pt 8):2253-62
pubmed: 16847121
PLoS One. 2014 Jul 15;9(7):e101807
pubmed: 25025380
Vaccine. 2002 May 31;20 Suppl 3:S34-9
pubmed: 12184362
Proc Natl Acad Sci U S A. 2016 Feb 16;113(7):1853-8
pubmed: 26755593
J Pharmacol Exp Ther. 2018 May;365(2):346-353
pubmed: 29535156
J Immunol. 2017 Jan 15;198(2):623-628
pubmed: 27986907
J Med Chem. 2018 Jan 11;61(1):329-343
pubmed: 29236495
J Exp Med. 2006 May 15;203(5):1249-58
pubmed: 16636134
Immunity. 2010 Oct 29;33(4):492-503
pubmed: 21029960
J Immunol. 2015 Jun 15;194(12):5604-8
pubmed: 25964495
J Immunol. 2015 Jun 15;194(12):5926-36
pubmed: 25972483
J Immunol. 2015 May 15;194(10):4836-45
pubmed: 25870238
J Immunol. 2016 Aug 15;197(4):1242-51
pubmed: 27412417
PLoS One. 2014 May 05;9(5):e96547
pubmed: 24797666
J Pharmacol Exp Ther. 2012 Apr;341(1):225-32
pubmed: 22262924

Auteurs

Christine Robinson (C)

a Hennepin Healthcare Research Institute (formerly Minneapolis Medical Research Foundation) , Minneapolis, MN , USA.

Carly Baehr (C)

a Hennepin Healthcare Research Institute (formerly Minneapolis Medical Research Foundation) , Minneapolis, MN , USA.
b Department of Veterinary Population Medicine , University of Minnesota , Minneapolis, MN, , USA.

Shirdi E Schmiel (SE)

c Scripps Research Institute , La Jolla, CA , USA.

Claudia Accetturo (C)

d Department of Pharmaceutics , Universita degli Studi di Milano , Milan , Italy.

Daniel L Mueller (DL)

e Center for Immunology , University of Minnesota , Minneapolis, MN , USA.
f Department of Medicine , University of Minnesota , Minneapolis, MN , USA.

Marco Pravetoni (M)

a Hennepin Healthcare Research Institute (formerly Minneapolis Medical Research Foundation) , Minneapolis, MN , USA.
e Center for Immunology , University of Minnesota , Minneapolis, MN , USA.
f Department of Medicine , University of Minnesota , Minneapolis, MN , USA.
g Department of Pharmacology , University of Minnesota , Minneapolis, MN , USA.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH